Last reviewed · How we verify
NCT05314725
Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial
Phase 2 trial testing SGLT2 inhibitor in Postoperative Hyperglycemia in 24 participants. Status unknown.
1 May 2023
Quick facts
| Lead sponsor | Zealand University Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 June 2022 |
| Primary completion | 1 May 2023 |
| Estimated completion | 1 June 2023 |
Drugs / interventions tested
- SGLT2 inhibitor — full drug profile →
- Placebo
Conditions studied
- Postoperative Hyperglycemia — all drugs for Postoperative Hyperglycemia →
- Stress Hyperglycemia — all drugs for Stress Hyperglycemia →
Sponsor
Zealand University Hospital
Who can join
Adults 18 to 85, any sex, with Postoperative Hyperglycemia or Stress Hyperglycemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to investigate the effect of an SGLT-2 inhibitor on postoperative hyperglycemia after acute abdominal surgery in patients without diabetes
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05314725
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SGLT2 inhibitor
Trials testing the same drug.
- NCT07360457 — GLP1 Analogues and the Risk of Osteoarthritis · not yet recruiting
- NCT07172971 — Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy · Phase 1 · not yet recruiting
- NCT07334145 — Effect of SGLT2 Inhibitors on Anemic CKD Patients · not yet recruiting
- NCT07063316 — SGLT2 Inhibitors and Renal Anemia in Japan: RWD · active not recruiting
- NCT06350487 — The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction · Phase 4 · not yet recruiting
Other Zealand University Hospital trials
Trials by the same sponsor.
- NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
- NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
- NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05314725 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
- Last refreshed: 6 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05314725.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing